10/7/2013

Cornerstone Pharmaceuticals announced that CPI-613, its myelodysplastic syndrome drug, has been given orphan drug status by the FDA. The altered energy metabolism directed drug candidate is in Phase I, I/II and Phase II trials focused on hematologic malignancies and solid tumors.

Related Summaries